Bamboo Therapeutics, Inc. A Wholly Owned Subsidiary Of Pfizer

Bamboo represents a community of researchers, clinicians, parents, regulatory scientists, and business professionals committed to providing hope to patients suffering from debilitating disease. Bamboo is focused on some of the most devastating neurological and neuromuscular diseases that affect children. Our lead therapeutic is a gene therapy product for the treatment of Duchenne muscular dystrophy. Bamboo's therapeutics are derived from an exclusive rAAV platform technology, and are manufactured using a proprietary scaled up process at an established GMP vector core facility recently purchased by the company.